Sanofi Files a Second Petition for IPR of Immunex’s Dupixent Patent

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

Sanofi-Aventis has filed a petition for IPR of Immunex Corporation’s U.S. Patent 8,679,487, directed to isolated human antibodies that compete with a reference antibody for binding to human interleukin-4 (IL-4) receptor.  The proceeding has been assigned the number IPR2017-01879.  The ‘487 patent is also at issue in district court litigation regarding Sanofi-Aventis and Regeneron’s Dupixent (dipolumab), and in IPR2017-01129, also filed by Sanofi, as we’ve previously reported.

Dupixent® (dipolumab) is marketed by Sanofi-Aventis and Regeneron and is indicated for the treatment of atopic dermatitis.

The petition and other selected documents related to IPRs on biologic patents are posted on our IPR tracker page.

Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide